Trial Profile
A Double-blind, Placebo-controlled Study in Healthy Volunteers to Determine the Safety and Tolerability of Single, Ascending Subcutaneous Doses of Sevuparin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Sevuparin (Primary)
- Indications Falciparum malaria; Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Modus Therapeutics
- 12 Jun 2023 According to a Modus Therapeutics media release, data were presented at the annual meeting of the European Hematology Association (EHA), on June 10 in Frankfurt am Main, Germany.
- 15 Jul 2019 Status changed from recruiting to completed.
- 25 Nov 2018 New trial record